RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of gemcitabine applied to the bladder
directly combined with different oral doses of everolimus and to assess the right doses.
Gemcitabine will be given at a fixed dose. Up to 3 dose levels of everolimus will be
evaluated. The purpose of the phase II part is to test the combination of gemcitabine applied
to the bladder directly combined with different oral doses of everolimus and to study the
effects of these two drugs together. The investigators want to find out what effects, good
and/or bad, this treatment has on the patient and the cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
New York University Novartis Pharmaceuticals University of Hawaii